Company profile
iRegene Therapeutics
Re-Defining Medicine for the Coming Generation.
- Industry
- Biotechnology Research
- Employees
- 3
- Headquarters
- Wuhan, Hubei
- Founded
- 2017
- LinkedIn followers
- 414
- Office locations
- 3
iRegene Therapeutics company summary
iRegene Therapeutics is a company in the Biotechnology Research industry, headquartered in Wuhan, Hubei, founded in 2017. On LinkedIn the company has around 3 employees and 414 followers. The company lists 3 office locations. Its listed specialties include regenerative medicine, stem cell therapy, neurology, retinal degenerative diseases, cardiology.
What technology does iRegene Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About iRegene Therapeutics
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. Our leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2. We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
Specialties
Where is iRegene Therapeutics located?
iRegene Therapeutics lists 3 office locations.
Compare companies similar to iRegene Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
iRegene Therapeutics iregene.com | Biotechnology Research | 3 | 2017 | Wuhan, Hubei |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about iRegene Therapeutics
What does iRegene Therapeutics do?
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. Our leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2. We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
How many employees does iRegene Therapeutics have?
iRegene Therapeutics has around 3 employees on LinkedIn.
Where is iRegene Therapeutics headquartered?
iRegene Therapeutics is headquartered in Wuhan, Hubei.
Where does iRegene Therapeutics have offices?
iRegene Therapeutics lists 3 office locations, including Wuhan, Hubei, CN; Singapore, 068914, SG; Suzhou, Jiangsu, CN.
When was iRegene Therapeutics founded?
iRegene Therapeutics was founded in 2017.
Build a lead list from companies like iRegene Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.